Shortsellers Say Gingko BioWorks Is ‘Colossal Synthetic Biology Scam'
One Of 2021’s Biggest Biotech IPOs
The company claims its synthetic biology technology will revolutionize manufacturing but its share have dipped after the fraud allegations.
You may also be interested in...
Troubled Zymergen will continue its ongoing restructuring efforts and Ginkgo, which has seen its own challenges since going public, will use Zymergen’s automation expertise to accelerate its growth.
Deal Snapshot: In its third biopharma collaboration this year, Ginkgo will apply its genetic engineering technologies to using Bacteroides for stable delivery of microbiome medicines.
2021 was a busy year in the medtech investment space. How will 2022 compare?